Andrew Weyrich

Andrew Weyrich leads microbiome oncology research focused on developing defined bacterial consortia to enhance immunotherapy efficacy. His work examines Bifidobacterium species as beneficial microbiome members that augment T cell priming and anti-PD-1 response. He has contributed to clinical development of SER-401, a microbiome therapeutic being tested in combination with checkpoint inhibitor therapy in melanoma.